ScholarLink (思领科)
错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prospective manipulation of the gut microbiome with microbial ecosystem therapeutic 4 (MET4) in HPV-related locoregionally-advanced oropharyngeal cancer squamous cell carcinoma (LA-OPSCC) undergoing primary chemoradiation: ROMA2 study

  • 期刊论文

  • 发表日期：

    2024年5月7日

查看全文
  • Marc Oliva,
  • Alya Heirali,
  • Geoffrey Watson,
  • Ashley M. Rooney,
  • Kyla Cochrane,
  • Sarah Jennings,
  • Rachel Taylor,
  • Minge Xu,
  • Ali Hosni,
  • Andrew Hope,
  • Scott V. Bratman,
  • Douglas Chepeha,
  • Ilan Weinreb,
  • Bayardo Perez-Ordonez,
  • Ricard Mesia Nin,
  • John Waldron,
  • Wei Xu,
  • Aaron R. Hansen,
  • Lillian L. Siu,
  • Bryan Coburn,
  • Anna Spreafico

摘要

Background

Gut microbiome modulation to boost antitumor immune responses is under investigation.

Methods

ROMA-2 evaluated the microbial ecosystem therapeutic (MET)-4 oral consortia, a mixture of cultured human stool-derived immune-responsiveness associated bacteria, given with chemoradiation (CRT) in HPV-related oropharyngeal cancer patients. Co-primary endpoints were safety and changes in stool cumulative MET-4 taxa relative abundance (RA) by 16SRNA sequencing. Stools and plasma were collected pre/post-MET-4 intervention for microbiome and metabolome analysis.

Results

Twenty-nine patients received ≥1 dose of MET-4 and were evaluable for safety: drug-related adverse events (AEs) occurred in 13/29 patients: all grade 1–2 except one grade 3 (diarrhea). MET-4 was discontinued early in 7/29 patients due to CRT-induced toxicity, and in 1/29 due to MET-4 AEs. Twenty patients were evaluable for ecological endpoints: there was no increase in stool MET-4 RA post-intervention but trended to increase in stage III patients (p = 0.06). MET-4 RA was higher in stage III vs I-II patients at week 4 (p = 0.03) and 2-month follow-up (p = 0.01), which correlated with changes in plasma and stool targeted metabolomics.

Conclusions

ROMA-2 did not meet its primary ecologic endpoint, as no engraftment was observed in the overall cohort. Exploratory findings of engraftment in stage III patients warrants further investigation of microbiome interventions in this subgroup.